A147patient population. Based on a representative population-based patient-cohort, the objective of this study was to develop a decision model that could reflect realworld practice and predict the costs throughout treatment pathway. Methods: All patients newly diagnosed with FL in the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) between 2004 and 2011 were followed until 2014 (n= 741). The mapped treatment pathways, alongside cost information derived from the National Tariff 2013/14, were incorporated into a discrete event simulation in order to reflect the heterogeneity of clinical characteristics, such as stage, and treatment options. Results: The annual cost of treating FL across the UK (population ~ 64 million) was estimated to be around £17 million. The predicted mean cost per patient from diagnosis to death was £10,202. Based on the initial treatment decision average costs were; £17,054 for those treated with chemotherapy (46%), £4,651 for those treated with radiotherapy (12%), and £2,185 for those managed by "watch-and-wait" (42%). The model's predicted costs per patient captured 95% of the actual costs calculated from empirical data, supporting the validity of the model. ConClusions: This is the first modelling study using 'real world' evidence to predict costs of entire FL treatment pathways. As several expensive new technologies/treatments for FL are on the horizon, future application of the model developed here could be used to assess their economic impacts and support healthcare decision makers, especially in the era of personalised medicine.

A861and myeloid leukemia (9.3%, n= 263) in Auditron. ConClusions: Although limited to the state of Sao Paulo, FOSP database provides substantial information on cancer treatment, from a large number of patients. Auditron presents a larger geographic coverage on the country and more detailed information on prescriptions, while FOSP does not provide detailed information on prescriptions.

The average length of hospitalizations per ICD ranged from 4.2 (stricture of artery) to 16.4 days (cardiac arrest), and the average cost per day of hospitalization varied from R$2.9 thousand (stroke) to R$9.4 thousand (CAD). These costs may still be underestimated, as study limitations include the lack of a standardized reporting process and ICD not being a mandatory information at the medical billing. ConClusions: Hospitalizations and procedures due to CVD heavily affect the private healthcare system, both economically and in occupation of hospital beds, tending to increase due to population ageing in Brazil. There is a significant unmet need for reducing risk factors and consequently CV events.

with drug-eluting stent placement cost an average of 47,053.16, patients with acute myocardial infarction who underwent revascularization cost an average of 55,585.20, patients with acute myocardial infarction who underwent revascularization and angioplasty with drug-eluting stent placement cost an average of 57,391.90, and patients with acute myocardial infarction who underwent angioplasty with drugeluting stent placement cost an average of 58,476.30. ConClusions: Private health insurances in Brazil provide treatment only for hospitalized patients instead of covering prophylactic drug treatment, a practice that might lead to higher expenditure on hospitalization and procedures for unmanaged cardiovascular diseases, where costs can range from 24,175.49 up to 58,476.30, an increase of 41%.

No abstract